On July 10, 2019, Celgene Inc. announced that Health Canada approved a Pomalyst (pomalidomide)-based triplet combination with bortezomib and dexamethasone as a new medication option for patients living with multiple myeloma. This is a new treatment option for those who have received at least one prior treatment regimen that included Revlimid (lenalidomide).
Dr Reece from Princess Margaret Cancer Centre was quoted as saying “…The Pomalyst-based triplet combination is a positive step forward in the treatment journey for multiple myeloma patients and their loved ones.”
While this new drug option is available and approved for sale in Canada, it is not yet covered through provincial governments.
Read the full press release